We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Model guidelines for Medicare drug formularies drafted by the U.S. Pharmacopeia (USP) do not provide patients with access to needed medicines and are in need of a comprehensive revision, according to the brand industry trade group.
Despite industry claims to the contrary, pharmaceutical manufacturers spend relatively little on R&D compared to what they spend on marketing, according to a former editor of the New England Journal of Medicine.
Consumer advocacy organization Public Citizen is calling for a federal investigation into whether four nonprofit seniors groups received $41 million from PhRMA in 2002 to support candidates friendly to the pharmaceutical industry.
Contrary to what the pharmaceutical industry claims, drugmakers spend relatively little on R&D compared to what they spend on marketing, according to a prominent industry critic who argues that U.S. big pharma should be subject to a national pricing scheme similar to one in Canada.
Pending legislation in California that would require pharmaceutical benefit managers (PBMs) to disclose information about their transactions with drugmakers could raise the cost of drugs, according to recent analysis by the FTC.
Houston-based devicemaker Cyberonics rejected a $524 million dollar merger offer from Advanced Neuromodulation Systems (ANS) last week, marking the second time in a month that Cyberonics has rebuffed ANS.
Indiana is the latest state to consider the importation option, saying it will move to import prescription drugs from Canada if the federal government doesn’t act by next March to lower drug prices, according to the state’s top elected official.
Eleven states and two healthcare organizations have signed on as partners in a national project designed to compare prescription drugs on the basis of efficacy — an initiative that aims to change the way drugs are purchased.
Some prominent medical journals will no longer publish the results of clinical trials unless the studies first have been registered at a publicly accessible online database.
Private drug plans competing for business under the Medicare prescription drug benefit will be able to negotiate drug price savings that are at least equal to what the government could achieve through direct price negotiations, according to the head of the Centers for Medicare & Medicaid Services (CMS).